

Shield Therapeutics plc
("Shield" or the "Company" or the "Group")

Grant of Share Options to Chief Executive Officer

London, UK, 14 October 2025: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency, announces that on 13 October 2025 it granted share awards in the form of options over ordinary shares in the capital of the Company ("Ordinary Shares") under Shield Therapeutics' Retention and Performance Share Plan ("RPSP") to the Group CEO as part of his 2025 annual equity grant.

In accordance with the requirements of the EU Market Abuse Regulations the following options have been granted to Anders Lundstrom, Chief Executive Officer, who is deemed a PDMR:

Name	Option Plan	Number of Ordinary Shares under Option	Vesting Date
Anders Lundstrom	RPSP	1,547,262	Three equal tranches over three years from the date of grant, subject to Mr Lundstrom remaining in office as at the date of vesting.

The proportion of total option awards to Anders Lundstrom is approximately 0.1% of the total number of AIM securities in issue at this time.

Anders Lundstrom currently holds 585,000 ordinary shares in the Company.

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")		
a)	Name	Anders Lundstrom	
2.	Reason for the notification		
a)	Position/status	Chief Executive Officer	
b)	Initial notification/ amendment	Initial Notification	
3.	Details of the Issuer		
a)	Name	Shield Therapeutics plc	
b)	LEI code	213800G74QWY15FC3W71	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument	Options over new Ordinary Shares	
	Identification code	ISIN: GB00BYV81293	
b)	Nature of the transaction	Grant of awards over new Ordinary Shares under the Company's Retention and Performance Share Plan.	
c)	Price(s) and volumes(s)	2025 RPSP Award	
		Price (£)	Volume
		0.015	1,547,262
d)	Aggregated information		
	- Aggregate volume	Awards granted over 1,547,262 shares in total	
	- Price	1.5p exercise price	
e)	Date of the transaction	13 October 2025	
f)	Place of the transaction	Outside of trading venue	

For further information please contact:

Shield Therapeutics plc

Anders Lundstrom, CEO
Santosh Shanbhag, CFO
Stephanie Hicks, Investor Relations

www.shieldtherapeutics.com

+44 (0) 191 511 8500
Investorrelations@shieldtx.com

Nominated Adviser and Joint Broker

Peel Hunt LLP

James Steel

+44 (0)20 7418 8900

Joint Broker

Cavendish Ltd

Geoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward

+44 (0)20 7220 0500

About Iron Deficiency and ACCRUFER®/FeRACCRU®

Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a 2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFER® has the potential to meet an important unmet medical need for both physicians and patients and is now the leading **#1 branded prescription oral iron the market today** (data source - IQVIA Xponent PlanTrak).

ACCRUFER®/FeRACCRU® (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA. The drug has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFER®/FeRACCRU®, including the product label, can be found at: www.accrufer.com and www.feraccru.com.

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company that delivers ACCRUFER®/FeRACCRU® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched ACCRUFER® in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU® is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFER®/FeRACCRU® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, with Kye Pharmaceuticals Inc. for Canada, and with VITAL-NET for Japan.

ACCRUFER®/FeRACCRU® has patent coverage until the mid-2030s.

ACCRUFER®/FeRACCRU® are registered trademarks of Shield Therapeutics.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHGPGRAUUPAGWC